South Korea Non-Hodgkins Lymphoma Market Expected to Grow Faster According to New Research Report 2023-2028

The South Korea Non-Hodgkins Lymphoma Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global South Korea Non-Hodgkins Lymphoma market. This report explores all the key factors affecting the growth of the global South Korea Non-Hodgkins Lymphoma market, including demand-supply scenario, pricing structure, profit margins, production, and value chain analysis.

Get PDF Sample Report Now! @ https://www.prudentmarkets.com/sample-request/141718/

Report Overview

The South Korea Non-Hodgkins Lymphoma market size stood at around USD xx billion in 2020 and is projected to reach xx billion by 2028, exhibiting a CAGR of around 6.2% during the forecast period.

Non-Hodgkin's lymphoma is a type of cancer that begins in lymphatic system, which is part of the body's immune system. In non-Hodgkin's lymphoma, white blood cells called lymphocytes grow abnormally and can form growths (tumours) throughout the body. Non-Hodgkin's lymphoma is a general category of lymphoma. There are many subtypes that fall in this category. Diffuse large B-cell lymphoma and follicular lymphoma are among the most common subtypes.

According to GLOBOCAN report South Korea reported 5,431 new cases of Non-Hodgkins Lymphoma in 2020 and ranked eleventh among other cancer sites. It had the 8th highest death rate with 2,320 death in year 2020 (death rate 2.6%). The five-year prevalence rate was 25.77 per 100,000.

Market Drivers

Rise in the prevalence of Non-Hodgkins Lymphoma, demand for innovative drugs and novel technologies, and an increase in the number of FDA approvals for Non-Hodgkins Lymphoma therapy drugs are the factors, that are propelling the market growth. Furthermore, an increase in public awareness about Non-Hodgkins Lymphoma, strong drug pipeline for the treatment of the disease, improved diagnostic techniques are the factors fuelling the market growth.

However, the high cost of drugs and various complications associated with them are acting as major restraints for the Non-Hodgkin lymphoma market.

 

To Know More About COVID-19 Impact On South Korea Non-Hodgkins Lymphoma Market @ https://www.prudentmarkets.com/sample-request/141718/

Market Segmentation

By Type:

On the basis of type Non-Hodgkin's lymphoma market segments are B-cell lymphoma and T-Cell lymphoma.

B-cell non-Hodgkin lymphoma (BNHL) comprises a heterogeneous group of lymphoid malignancies that differ in their clinical presentation and progression. The most common type of mature BNHL in adults is diffuse large B-cell lymphoma (DLBCL), which comprises approximately 46% of mature BNHL in Korea. The prognosis of BNHL has improved in the last decade, attributed primarily to the addition of rituximab to standard chemotherapy regimens.

By Therapy:

According to therapy, liver cancer market segments are targeted therapy, radiation therapy, chemotherapy, and others.

Top Players

Domestic companies are performing well in the Non-Hodgkin's lymphoma market and competing with the affluent global players. For instance, Truxima™ (rituximab) was the first biosimilar monoclonal antibody (mAb) approved for the treatment of haematological cancers, including diffuse large B-cell lymphoma, follicular lymphoma, and others. The drug was discovered and developed by Celltrion Healthcare; a company based in South Korea. Truxima™ received marketing approval from the Ministry of Food and Drug Safety in South Korea in November 2016.

In 2020, Celltrion also gained approval to launch its autoimmune disease drug Remsima which is a biosimilar of Janssen Biotech's Remicade (infliximab). Remsima is currently in phase three clinical trial in the United States. Celltrion aims to complete the trial by 2021 and launch the drug in 2022.

Boryung Pharmaceutical Korea announced its approval for Phase 1 clinical studies on its anti-cancer therapy "BR2002" from the U.S. Food and Drug Administration (FDA) in 2019. It is due to be completed in February 2024. BR2002 represents the company's efforts to push into the global anti-cancer treatment market.

Prudent Markets provides attractive discounts that fit your needs. Customization of the reports as per your requirement is also offered. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Speak To Our Analyst For A Discussion On The Above Findings, And Ask For A Discount On The Report @ https://www.prudentmarkets.com/discount-request/141718/

The report covers the competitive analysis of the market. As the demand is driven by a buyer's paying capacity and the rate of item development, the report shows the important regions that will direct growth. This section exclusively shares insight into the budget reports of big-league members of the market helping key players and new entrants understand the potential of investments in the Global South Korea Non-Hodgkins Lymphoma Market. It can be better employed by both traditional and new players in the industry for complete know-how of the market.

Strategic Points Covered in Table of Content of Global South Korea Non-Hodgkins Lymphoma Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the South Korea Non-Hodgkins Lymphoma market
Chapter 2: Exclusive Summary - the basic information of the South Korea Non-Hodgkins Lymphoma Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the South Korea Non-Hodgkins Lymphoma
Chapter 4: Presenting the South Korea Non-Hodgkins Lymphoma Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country
Chapter 6: Evaluating the leading manufacturers of the South Korea Non-Hodgkins Lymphoma market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Any Questions? Feel Free To Enquire Here. We Will put you on the Right Path @ https://www.prudentmarkets.com/enquiry-request/141718/

Free Customization on the basis of client requirements on Immediate purchase:
1- Free country-level breakdown of any 5 countries of your interest.
2- Competitive breakdown of segment revenue by market players.

Customization of the Report:
This report can be customized to meet the client's requirements. Please connect with our sales team (sales@prudentmarkets.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +91 83560 50278 || USA/Canada(Toll Free): 1800-601-6071 to share your research requirements.

Get ready to Recognize the pros and cons of the regulatory framework, local reforms, and its effect on the Industry. Understand how the Leaders in Intelligent Network are keeping themselves one stage forward with our most up-to-date survey analysis.

In conclusion, the South Korea Non-Hodgkins Lymphoma Market report is a genuine source for accessing the research data which is projected to exponentially grow your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis and PESTLE analysis is also incorporated in the report.

Contact Us:
Allan Carter
Andheri, Maharashtra, 400102
USA/Canada(Toll Free): 1800-601-6071
Direct Line: +91 83560 50278
Mail: sales@prudentmarkets.com
Web: www.prudentmarkets.com

About Us:
We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy.

This release was published on openPR.